A groundbreaking new approach to HIV prevention has emerged with a twice-yearly injectable treatment, offering a potential alternative to daily medication. While the scientific breakthrough promises greater convenience and potentially higher adherence rates, critical debates are already unfolding over equitable access and distribution. Experts warn that ensuring fair availability could determine whether the innovation benefits those most at risk or exacerbates existing disparities. The ethical and logistical challenges of implementation now stand as major hurdles alongside the medical promise.
A twice-yearly injection could revolutionise HIV prevention, but who gets access raises bigger questions.
